
Photocure ASA
OSE:PHO

Photocure ASA
Revenue
Photocure ASA
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Photocure ASA
OSE:PHO
|
Revenue
kr525.4m
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
15%
|
|
V
|
Vistin Pharma ASA
OSE:VISTN
|
Revenue
kr429.5m
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
N
|
Navamedic ASA
OSE:NAVA
|
Revenue
kr531.4m
|
CAGR 3-Years
24%
|
CAGR 5-Years
23%
|
CAGR 10-Years
9%
|
|
S
|
SoftOx Solutions AS
OSE:SOFTX
|
Revenue
kr13.3m
|
CAGR 3-Years
29%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
Photocure ASA
Glance View
Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.

See Also
What is Photocure ASA's Revenue?
Revenue
525.4m
NOK
Based on the financial report for Dec 31, 2024, Photocure ASA's Revenue amounts to 525.4m NOK.
What is Photocure ASA's Revenue growth rate?
Revenue CAGR 10Y
15%
Over the last year, the Revenue growth was 5%. The average annual Revenue growth rates for Photocure ASA have been 13% over the past three years , 13% over the past five years , and 15% over the past ten years .